Save time and jump to the most important pieces.
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company") today reported that it received a notice (the "Notice) on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule") as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Form 10-K") in a timely manner. This Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market. Under Nasdaq rule
ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco
PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company") today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation ("Symetryx") and their subsequent press release issued on September 6, 2023. "The NeuBase Board of Directors ("Board") appreciates input from its shareholders. The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on maximizing shareholder value. The Board does not believe that shareholder value will be enhanced by issuing the special $1 per share dividend Symetr
SC 13G/A - NeuBase Therapeutics, Inc. (0001173281) (Subject)
SC 13D/A - NeuBase Therapeutics, Inc. (0001173281) (Subject)
SC 13D/A - NeuBase Therapeutics, Inc. (0001173281) (Subject)
5 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)
4 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)
3/A - NeuBase Therapeutics, Inc. (0001173281) (Issuer)
HC Wainwright & Co. reiterated coverage of NeuBase Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously
HC Wainwright & Co. reiterated coverage of NeuBase Therapeutics with a rating of Buy and set a new price target of $18.00 from $15.00 previously
PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company") today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation ("Symetryx") and their subsequent press release issued on September 6, 2023. "The NeuBase Board of Directors ("Board") appreciates input from its shareholders. The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on maximizing shareholder value. The Board does not believe that shareholder value will be enhanced by issuing the special $1 per share dividend Symetr
URGES BOARD TO CONSIDER A $1 DIVIDEND TORONTO, Sept. 6, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc. (NASDAQ:NBSE) ("Neubase"). Symetryx is now urging the Board to issue a special $1 per share dividend. Symetryx has bought these shares on the open market and intends to engage with the management of Neubase to chart the best path forward for shareholders. Neubase, as disclosed in its previous news releases, is currently undergoing a strategic review of the company's operations. Symetryx notes that for the quarter ended June 30, 2023, Neubase reported approximate cash bala
Data show that Stealth Editors™ achieve ex vivo gene editing using simple synthetic reagents to harness the cell's own high-fidelity editing machineryData show that Stealth Editors™ do not elicit a cell-based immunity and promise a non-immunogenic in vivo solution Data show that Stealth Editors™ can be encapsulated via established lipid nanoparticle technologies promising a non-immunogenic delivery solution and a de-risked pathway to address therapeutic targets in the liverData featured in an oral presentation at the American Society of Gene & Cell Therapy ("ASGCT") 2023 Annual Meeting Company to present additional data showcasing gene editing capabilities of Stealth Editors™ throughout rema
8-K - NeuBase Therapeutics, Inc. (0001173281) (Filer)
DEFA14A - NeuBase Therapeutics, Inc. (0001173281) (Filer)
8-K - NeuBase Therapeutics, Inc. (0001173281) (Filer)
ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco
Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to present new rodent pharmacokinetic (PK) and bioavailability data in an oral presentation at an upcoming scientific meeting; expects to submit an IND application to the U.S. Food and Drug Administration (FDA) in the fourth quarter (Q4) of calendar year (CY) 2022Good Manufacturing Practice (GMP) manufacturing to support Phase 1/2 clinical trials for DM1 program successfully implemented Expects to nominate a development candidate and initiate scale-up and toxicology activities for a systemically administered, allele-selective candidate for the Hun
PITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Todd P. Branning as Chief Financial Officer (CFO). Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and investor relations for several publicly traded pharmaceutical companies. "Todd brings the highest level of sophistication in finance to NeuBase," said Dietrich A. Stephan, Ph.D., Founder, CEO and Ch